Physician profile
Daniel John Ferraro
NPI 1629237409
$6,727.91
in general payments reported to CMS, 2019-2025
13 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.76 · 2022: $40.88 · 2023: $6,403 · 2024: $98.78 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,027 · Food and Beverage: $621 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,027.35 |
| Food and Beverage | $620.92 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zap Surgical Systems, INC. | $6,319.38 | 2023 | Zap-X Radiosurgery System, Zap-X Mv Imager, Zap-X Treatment Planning Software |
| Novartis Pharmaceuticals Corporation | $101.95 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.09 | 2023-2025 | |
| Pfizer INC. | $51.85 | 2022-2023 | |
| Siemens Medical Solutions USA, INC. | $32.48 | 2024 | Halcyon |
| Idorsia Pharmaceuticals US INC | $27.86 | 2025 | Quviviq |
| Astellas Pharma US INC | $26.66 | 2025 | Xtandi |
| Gilead Sciences, INC. | $21.93 | 2024 | Trodelvy |
| Janssen Biotech, INC. | $21.34 | 2024 | Rybrevant |
| Novocure INC. | $17.76 | 2021 | |
| Myriad Genetic Laboratories, INC. | $13.42 | 2022 | |
| Urovant Sciences INC | $13.30 | 2022 | |
| Pharmaand Gmbh | $12.89 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ferraro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.